Morphea is a rare autoimmune disease characterized by inflammation and fibrosis of the skin and soft tissue. Its etiology remains unknown, but several theories have been postulated and assert the interplay between genetic, environmental and immune factors. Currently, there is no cure for morphea. However, by investigating the cells, mediators, and pathways involved in disease pathogenesis, new potential therapies have been identified to prevent fibrosis, disfigurement, and physical impairment caused by disease progression. In the setting of COVID-19 pandemic, tocilizumab, an IL-6 antagonist, has gained attention due to a potential role in management of severe cases of infection with SARS-CoV-2. In recent years, several cases of morphea successfully treated with tocilizumab have been reported. This article reviews morphea cases treated with tocilizumab and provides new insights into its role in the management of the disease.